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Objective. To investigate the ability of two-dimensional longitudinal strain echocardiography (2DST), to detect the early
doxorubicin cardiotoxicity. Patients and Methods. The study included 25 children with newly diagnosed acute lymphoblastic
leukemia (ALL) aged 5–15 years and 30 healthy control children. They had echocardiographic examination with conventional
2-dimensional (2D), pulsed tissue Doppler (PTD), and 2DST echocardiography before and within 1 week after doxorubicin
treatment. Results. There was no signiﬁcant diﬀerence in left ventricle (LV) systolic and diastolic functions measured by
conventional 2-D and PTD echocardiography between patients and controls. However, there was signiﬁcant decrease in LV global
and peak systolic strain detected by 2-DST echocardiography in study group than control. After doxorubicin treatment, there
was no signiﬁcant diﬀerence in LV systolic and diastolic functions measured by conventional 2-D and PTD echocardiography
than before treatment except for prolonged IVCT and IVRT, but LV global and peak systolic strain was signiﬁcantly lower after
treatment. Conclusion. 2-D longitudinal strain echocardiography was more sensitive than conventional 2-D and PTD in detecting
the early LV doxorubicin-induced cardiotoxicity in children with ALL.
1.Introduction
Doxorubicin is one of the most eﬀective available anthracy-
cline chemotherapeutic agents that have been widely used
in the treatment of pediatric malignancies. Its introduction
has led to the successful treatment of childhood cancer
with improved survival rates. Nearly two-thirds of survivors
have one or more related chronic medical problems and
may require multidisciplinary care [1]. Because doxorubicin
plays a key role in the treatment of many malignancies, its
loss from the ﬁeld of cancer treatments would lead to a
dramatic reduction in cure rates. Its eﬃcacy is often limited
by its related cardiotoxicity, which leads to cardiomyopathy
that may evolve into heart failure [2–4]. Cardiotoxicity can
arise acutely, during or shortly after treatment and regardless
of dose in the form of cardiac arrhythmias, for example,
sinus tachycardia, ventricular, and supraventricular. Peri-
carditis, potentially fatal congestive heart failure, and acute
pulmonary edema can also occur during doxorubicin ther-
apy caused by myocyte necrosis as a result of increased
cardiac apoptosis and alteration of cardiac cytochrome P450
expression and arachidonic acid metabolism [5, 6].
Chronic dose-related cardiotoxicity is the most common
and dangerous and can manifest as cardiac failure, months
or even years after the completion of treatment and is
thought to be related to myocardial toxicity [7]. Multiple
risk factors for doxorubicin-associated cardiotoxicity have
enabled clinicians to deﬁne a high-risk population for2 ISRN Pediatrics
cardiotoxicity. However, some low-risk patients can develop
cardiotoxicity. On the other hand, not all high-risk patients
develop cardiotoxicity [8].
The increase in prevalence of doxorubicin cardiotoxicity
is partly due to improved diagnosis and partially owing
to longer follow-up periods [9]. To detect cardiac damage,
the adopted diagnostic approach depended mainly on the
estimation of left ventricle ejection fraction (LVEF) or
left ventricle fractional shortening (LVFS). Left ventricular
systolic function (EF or FS) after doxorubicin therapy is gen-
erally assessed using M-mode and 2D echocardiography. On
thebasisofdimensionalchangesandvolumecalculations,FS
and EF are calculated. This approach showed low sensitivity
toward early prediction of cardiomyopathy; that is, why
new modalities are being introduced into clinical trials.
During the last decade, new echocardiographic techniques
for evaluating myocardial function have been introduced.
The 2-dimensional strain echocardiography (2DSE) is a
relatively new echocardiographic modality based on mea-
surement of myocardial deformation using speckle-tracking
from B mode images. Myocardial velocity and deformation
imaging, namely, strain and strain rate imaging, have been
demonstrated to have potential value for the quantiﬁcation
of global and regional systolic and diastolic myocardial
function. It seems that regional dysfunction can be detected
earlier than global dysfunction [10]. This might provide the
rationale to start treatment of doxorubicin cardiotoxicity
early in asymptomatic patients.
More studies are needed to deﬁne the best predictive
parameters for those patients at risk of developing LV dys-
function who might beneﬁt from an early start of treatment
[11, 12]. The aim of the presenting work was to investi-
gate the ability of echocardiography, especially the recent
modalities as two-dimensional longitudinal strain echocar-
diography, to detect early cardiotoxic eﬀect of doxorubicin
received before and after the induction therapy in children
with acute lymphoblastic leukemia (ALL).
2. Patientsand Methods
A group of 25 children with newly diagnosed acute lym-
phoblastic leukemia between 5 and 15 years of age presented
to the Hematology and Oncology Unit, the Pediatric Depart-
ment, Faculty of Medicine, Tanta University, Egypt, who met
the inclusion criteria, were included in the study from March
2008 to March 2010. Thirty healthy children of matched age
and sex were studied as a control group.
2.1. Inclusion Criteria. Newly diagnosed children with acute
lymphoblastic leukemia conﬁrmed by complete blood pic-
ture, bone marrow examination, and immunophenotyping
by ﬂow cytometry and ﬂuorescence in situ hybridization
(FISH) technique.
2.2.ExclusionCriteria. Previouschemotherapyorradiother-
apy, presence of any cardiac disease either congenital or
acquired, any cardiac lesion detected in baseline echocardio-
graphy, any associated systemic disease that can aﬀect the
cardiac function, and/or medication that can aﬀect cardiac
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Figure 1: Pulsed-wave Doppler pattern of mitral inﬂow. It shows
the peak velocities during early diastole (E) and atrial contraction
(A).
function, such as angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, diuretics, or beta-blockers.
All children subjected to full history taking, thorough
clinical examination, complete blood picture (CBC), ery-
throcyte sedimentation rate (ESR), serum uric acid, and liver
and renal function tests. All children underwent echocardio-
graphic Doppler examination and measurement of troponin
I(cTnI),andcreatinephosphokinaseCPK(MB)levelsbefore
and within 1 week of starting the doxorubicin treatment.
All patients were subjected to the protocol of therapy in
induction of remission which showed in Table 1.
Echocardiographic images were obtained using a Vivid
7 ultrasound machine (GE Medical System, Horten, Nor-
way with a 3.5-MHz multifrequency transducer). To avoid
intraobserver variability, 2 examinations each time were
performed by the same operator for each patient in 2
diﬀerent settings within 2 days. All children were examined
in a semi-supine, left lateral position and according to the
recommendation of the American Society of Echocardio-
graphy [13]. M-mode and two-D echocardiography were
done to asses left ventricular (LV) internal dimensions,
ejection fraction (EF), and fraction shortening (FS). Mitral
ﬂow early-phase ﬁlling velocity (E), peak atrial phase ﬁlling
velocity (A), and E/A ratio were recorded by pulsed-wave
Doppler in the apical 4-chamber view where the sample
volume was best positioned in the left ventricle at the tips
of the valve leaﬂets (distal to the annulus) (Figure 1).
2.3. Pulsed Tissue Doppler Image (TDI). Pulsed tissue dop-
pler imaging was done using pulsed wave DTI ﬁlters, with
a sample volume 5.5mm, and frame rates of greater than
150fps were recorded. The baseline was adjusted to low-
velocity range (−20 to 20cm/s) with minimal gain setting.
The sample volume was placed within the myocardium
equidistant from the endocardial and epicardial borders.
Eﬀort was done to minimize the angles as much as possible.ISRN Pediatrics 3
Table 1: The protocol of induction of remission in children with newly diagnosed acute lymphoblastic leukemia in the Hematology and
Oncology Unit, the Pediatric Department, Faculty of Medicine, Tanta University.
Drug Intake route Dose Instructions
Vincristine IV 1.5mg/m2 Days 8, 15, 22, and 29
L-Asparaginase IM 10000IU/m2 3t i m e saw e e kf o r9d o s e s
Prednisone PO 60mg/m2/day In TID: days 29–32
Prednisone PO 30mg/m2/day In TID: days 29–32
Prednisone PO 15mg/m2/day In TID: days 33–35, then
discontinued on day 36
Triple therapy: Ara-C,
methotrexate, and
hydrocortisone
Intrathecal Doses adjusted to the age On days 1, 15, and 29
Conventional doxorubicin IV 30mg/m2 Days 8, 15, 22, 29
IV: intravenously, IM: intramuscularly, PO: orally, TID: on three divided doses daily.
IVCT IVRT
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Figure 2: Lateral mitral annular tissue Doppler tracing. s : peak velocity during ventricular systole; e : peak velocity during early ventricular
diastole; a : peak velocity during atrial contraction; IVCT: isometric (isovolumic) contraction time; IVRT: isometric (isovolumic) relaxation
time.
From the apical 4-chamber planes, using pulsed-wave TDI,
the myocardial velocity curves of septal and lateral mitral
valve annuli were recorded. The ECG was connected and
traced simultaneously to deﬁne and to time the cardiac
cycle events. The beginning of QRS complex was used as a
reference point (Figure 2).
2.4. Velocities and Interval Measurements. The s wave reﬂects
the systolic function of left ventricle (LV). The e /a 
(early/atrial) ratio of mitral valve annulus reﬂects the
diastolic function of LV. Isometric contraction time (IVCT)
was deﬁned as the time duration between the beginnings of
QRS complex in the ECG to the beginning of DTI systolic (s)
wave. Isometric relaxation time (IVRT) was deﬁned as the
interval between the end of s wave and the beginning of the
e  wave. At least 10 cardiac cycles were recorded from each
site on a strip-chart recorder at a speed of 100mm/s.
2.5. 2D Longitudinal Strain Echocardiogram Images. Were
obtained using the 3 standard apical views, apical long axis
(ALX), apical 4-chamber, and apical 2-chamber views, and
parameters obtained represented the average of 10 cardiac
cycles, with a frame rate of 65fps, and all segmental data (17
segments) were represented. We used automated function
imaging that enables only the assessment of longitudinal
strain available in Vivid 7 ultrasound machine to measure
averageLVglobalpeaksystolicstrain(G),globalpeaksystolic
strain in 3 standard apical views, and segmental peak systolic
strain in; basal, mid and apical segments of anteroseptal,
anterior, lateral, posterior, inferior, and septal LV walls [10].
The images were transferred to the EchoPACS workstation
with Q analysis software Version 4.0.3 (General Electric,
Waukesha, WI, USA) for processing (Figures 3, 4,a n d5).
Five milliliter of blood was transferred to plastic tubes
to estimate cTnI and CPK-MB levels. Serum and plasma
samples were prepared within 30 minutes of blood sampling
in a precooled centrifuge and were immediately frozen and
stored at 70◦C until used for analysis. The assessment of
cTnI blood levels was performed with Chiron Bayer ACS 180
chemiluminescent diagnostic test. This test is characterized4 ISRN Pediatrics
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Figure 3: Figure 3: Eye bull projection for normal 2D strain (red
colored) for one of the control group. GS =− 22.9%.
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Figure 4: 2D strain echocardiography in patient with doxorubicin-
induced cardiotoxicity.
by a high sensitivity, with a lower limit of detectability of
0.03ng/mL. The upper limit of the normal cTnI value is
0.1ng/mL.
Serum creatine phosphokinase isoenzyme MB (CPK-
MB) activity level was measured by immunochemilumino-
metric assay (Chemilumi ACS, Centaur; Bayer Medical Co.
Ltd., Tokyo, Japan), which have an upper reference limit of
5ng/mL[14]. All parents signed a written informed consent
before enrolment into the study. The local Institutional
Research Ethics Committee approved the study protocol.
The power level of the number of cases in the study was
more than 90%. Statistical analysis was performed with Sta-
tistical Package for Social Science (SPSS version 17). Data are
presented as mean (±SD) values. Comparison between the
studied groups was performed with Student’s t-test, with P<
0.05 considered statistically signiﬁcant. Wilcoxon’s signed
rank test was used to assess the normality of distributions of
the data. The Bonferroni correction/adjustment procedure
was done to avoid “signiﬁcance” due to chance only, in
multiple comparison with echocardiographic parameters.
Correlation between variables was evaluated using Pearson’s
correlation coeﬃcient [15].
3. Results
The demographics and clinical characteristics of children
withALLandthecontrolgroupwereshowninTable 2.There
were no signiﬁcant diﬀerences between children with ALL
and the controls as regard to age and sex. The heart rate
(HR) and respiratory rate (RR) were signiﬁcantly higher in
children with ALL than those in the controls (P<0.001)
while hemoglobin% (HB%), systolic blood pressure (SBP),
diastolic blood pressure (DBP), and body mass index (BMI)
were signiﬁcantly lower in children with ALL than those in
controls (P<0.001).
Echocardiographic data of children with ALL and the
controls before starting the doxorubicin treatment were
shown in Table 3. The FS (which represents the LV systolic
function) was signiﬁcantly higher in leukemic children than
that in the control group though still within the normal
values (P<0.05); however, the E/A (which represents
the LV diastolic function) showed no signiﬁcant diﬀerences
between the 2 groups (P>0.05). The table also showed that
there were no signiﬁcant diﬀerences in the tissue Doppler
p a r a m e t e r s :s ,I V C T ,e , a , e /a  ratio, and IVRT (P>0.05).
The global strain (G) of the LV was signiﬁcantly lower in
leukemic children than that in the control group (P<0.05),
and there was less signiﬁcant decrease in the peak systolic
strain in apical 2-chamber view (P<0.05), while there was
no signiﬁcant change in the other views apical long axis and
apical 4-chamber views (P>0.05 for both views).
The echocardiographic examination data in the patient
group before and after the doxorubicin treatment are shown
in Table 4. It showed more signiﬁcant reduction of FS
after treatment with doxorubicin (P<0.05). However
the s wave measured by the tissue Doppler showed no
signiﬁcant diﬀerence before and after treatment. Meanwhile
the IVCT showed signiﬁcant prolongation after treatment.
On the other hand, the diastolic function of the LV showed
no signiﬁcant diﬀerences both by conventional and tissue
Doppler data except for IVRT which showed signiﬁcant
prolongation after the treatment with doxorubicin (P<
0.001). In 2D longitudinal strain echocardiogram, the peak
systolicandglobalstrainsshowedsigniﬁcantreductioninthe
apical long-axis view (P<0.01 and <0.05, respectively, but
showed no signiﬁcant diﬀerences in both apical 4-chamber
and apical 2-chamber views (P>0.05).
Table 5 showed signiﬁcant increase in the serum cTnI
level in the children with ALL after doxorubicin treatment
thanbeforestartingthetreatment.Ontheotherhand,serum
CPK (MB) level showed no signiﬁcant change in those
childrenafterdoxorubicintreatment.However,Figures6andISRN Pediatrics 5
Table 2: Comparison of demographic data in controls and ALL children group.
Control (n-30) Patient Group (n-25) t-test P value
Age ± SD (yr) 9.2 ±2.99 ±2.6 0.47 0.64
SexM:Fratio 7:8 13:12 0.6 0.53
Hb%± SD 12.8 ±1.19 .4 ±1.05 10.2 <0.001∗
HR ± SD (beat/min) 83.3 ±8.08 7 .0 ±8.7 10.3 <0.001∗
RR ± SD (cycle/min) 21.1 ±2.52 2 .4 ±2.86 . 6 <0.001∗
SBP ± SD (mmHg) 100.0 ±6.29 0 .8 ±5.27 . 3 <0.001∗
DBP ± SD (mmHg) 56.7 ±6.34 9 .2 ±5.9 15.6 <0.001∗
BMI ± SD (Kg/m2)1 8 .4 ±1.72 2 .0 ±2.56 . 1 <0.001∗
M:F(male-to-femaleratio);Hb%(hemoglobinpercent);HR(heartrate),RR(respiratoryrate);SBP(systolicbloodpressure)DBP(diastolicbloodpressure);
BMI (body mass index).
Table 3: Comparison between conventional echo, tissue Doppler parameters, and peak systolic strain in the main three longitudinal views
of LV in controls and patients group before starting doxorubicin treatment.
Control (n-30) Patient group (n-25) t-test P value
FS % 35.78 ±5.16 40 ±4.87 2 0.05∗
E( m / s e c ) 0 .87 ±0.11 0.77 ±0.24 2.1 0.04∗
A( m / s e c ) 0 .52 ±0.13 0.73 ±0.13 3.3 0.005∗
E/A 1.51 ±0.41 .60 ±0.42 1.1 0.09
s( m / s e c ) 0 .07 ±0.02 0.06 ±0.014 0.9 0.15
IVCT (ms) 83.1 ±4.98 3 .6 ±4.2 1.8 0.08
e  (m/sec) 0.12 ±0.03 0.127 ±0.011 0.5 0.52
a  (m/sec) 0.07 ±0.02 0.072 ±0.020 0.8 0.25
e /a  1.88 ±0.49 1.9 ±0.4 0.75 0.53
IVRT (ms) 66.2 ±3.66 7 .1 ±3.3 1.99 0.057
ALX −22.2 ±5.8% −21.1 ± 5.3% 0.53 0.59
A4C −21±2.4% −18.9 ± 4.5% 1.86 0.07
A2C −21±3.4% −16.9 ± 7.3% 2.3 <0.03∗
G −21.5 ±2.2% −18.7 ± 4.5% 2.7 <0.01∗
FS: fractional shortening, E: peak early ﬁlling velocity, A: Peak atrial phase ﬁlling velocity, s : tissue Doppler peak mitral annulus systolic velocity, e :t i s s u e
Doppler mitral ﬂow early-phase ﬁlling velocity, a : tissue Doppler peak atrial phase ﬁlling velocity, IVCT: isometric contraction time, IVRTL: Isometric
relaxation time, ALX: apical long axis, A4C: apical 4-chamber, A2C: apical 2-chamber, views, and G: global peak systolic strain.
Table 4: Comparison between eﬀects on patient group before and after doxorubicin on conventional echo and tissue Doppler parameters.
Patient group before (n-25) Patient group after (n-25) t-test P value
FS % 40 ±4.87 33.5 ±6.58 2.508 0.02∗
E( m / s e c ) 0 .77 ±0.24 0.78 ±0.24 0.214 0.83
A( m / s e c ) 0 .73 ±0.13 0.63 ±0.13 1.244 0.32
E/A 1.60 ±0.42 1.5 ±0.37 4.4 1.06
s( m / s e c ) 0 .063 ±0.014 0.062 ±0.01 0.18 0.56
IVCT (ms) 86.5 ±4.28 5 .9 ±0.8 2.4 0.02∗
e  (m/sec) 0.127 ±0.011 0.132 ±0.009 1.099 0.26
a  (m/sec) 0.072 ±0.020 0.061 ±0.011 1.468 0.52
e /a  1.852 ±0.396 2.146 ±0.373 1.708 0.105
IVRT (ms) 67.1 ±3.28 7.1.8 ±3.28 5.8 <0.001∗
ALX −21.13 ±5.26% −13.28 ±3.69% 3.859 0.001∗
A4C −18.91 ±4.51% −17.27 ±4.19% 0.841 0.41
A2C −16.87 ±7.25% −14.75 ±3.56% 0.829 0.42
G −18.65 ±4.52% −15.10 ±2.45% 2.182 0.04∗
FS: fractional shortening, E: peak early ﬁlling velocity, A: Peak atrial phase ﬁlling velocity, s : tissue Doppler peak mitral annulus systolic velocity, e :t i s s u e
Doppler mitral ﬂow early-phase ﬁlling velocity, a : tissue Doppler peak atrial phase ﬁlling velocity, IVCT: isometric contraction time, IVRTL: Isometric
relaxation time, ALX: apical long axis, A4C: apical 4-chamber, A2C: apical 2-chamber, views, and G: global peak systolic strain.6 ISRN Pediatrics
(a) (b)
(c)
Figure 5: Examples of global longitudinal strain measures from the 3 standard apical views. Quad screen views from A4C (top), A2C
(middle), and ALX (bottom: in each, the upper left quadrant shows tracking and also average peak strain for the segments measured (given
as GS). Upper right quadrant shows color-coded segmental strain curves and average strain curve (dashed line). Bottom left quadrant
graphically denotes peak strain in each segment. Lower right quadrant depicts anatomic M-mode.
Table 5: Comparison between troponin I and CPK (MB) in patient group before and after doxorubicin.
Patient group before (n-25) Patient group after (n-25) t-test P value
Troponin I (ng/mL) 0.055 ±0.003 0.061 ±0.005 7.8 0.002∗
CPK (MB) (U/L) 50.60 ±8.55 48.61 ±6.56 0.185 0.62
CPK MB: creatinine phosphokinase cardiac.
7 showed no correlation between the LV global strain (G)i n
the long axis view and both the cTn I and CPK (MB) level.
4. Discussion
Doxorubicin-induced cardiotoxicity is suggested to be
through production of oxygen free radicals and highly
reactive hydroxyl radicals and peroxynitrite which induce
apoptosis and cardiac myocytes damage as the heart is par-
ticularly poorly protected against oxidative stress [16]. Other
mechanisms implicated in the pathogenesis of doxorubicin-
induced cardiotoxicity are lipid peroxidation, gene expres-
sion reduction, nucleic acid and protein synthesis inhibition,
vasoactive amines release, adrenergic function alteration,
calcium handling aberration, impairment of mitochondrial
creatinine kinase, and induction of nitric oxide synthase
[17]. Echocardiography is one of the most widely used
noninvasive methods for early detection and monitoring of
doxorubicin-induced cardiotoxicity. Left ventricular systolic
function evaluation by measuring the ejection fraction or
fractional shortening is the most commonly used method
to early detect doxorubicin-induced cardiotoxicity either by
nuclear methods or by echocardiography [17].
Early detection of doxorubicin cardiotoxicity is of para-
m o u n ti m p o r t a n c ea si ta l l o w st h eu s eo fc a r d i o p r o t e c t i v e
agents dexrazoxane or carvedilol. In the current study, 3
echocardiographic modalities were used to early detect the
doxorubicin-induced cardiotoxicity: the conventional 2D
Doppler echocardiography by measuring the fraction short-
ening as well as the E/A ratio, the pulsed tissue Doppler by
measuringtheswave,IVCT,e wave,a wave,e /a wave,and
IVRT,andlastlythe2Dlongitudinalstrainechocardiography
by assessment of LV longitudinal strain.
The fraction shortening showed a tendency towards
becoming statistical signiﬁcantly higher in the patients
group when compared to the control. This diﬀerence canISRN Pediatrics 7
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Figure 6: Correlation between troponin I and GS in ALL children
after doxorubicin treatment.
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Figure 7: Correlation between CPK (MB) and GS in ALL children
after doxorubicin treatment.
be explained by the presence of associated anemia and
tachycardia secondary to leukemia (hyperdynamic heart).
After doxorubicin treatment, the FS showed signiﬁcant
reduction despite still being within the normal limits. This
reduction was either due to the correction of anemia prior to
statingthecytotoxictherapyorasasideeﬀectoftherapywith
doxorubicin. However, FS has many limitations as regard to
the diﬃculty in accurate measurement and being aﬀected
by preload, after load, heart rate, desynchrony, as well as
myocardial contractility [18]. The transmitral E/A ratio
measured by conventional Doppler showed no signiﬁcant
diﬀerence between patients group and controls and also in
the patients group before and after doxorubicin treatment.
These ﬁndings disagreed with that of Iarussi et al. who found
that E/A ratio was signiﬁcantly reduced after doxorubicin
treatment. This diﬀerence in the results could be because
theystudiedthelatecardiotoxicityafter1yearofdoxorubicin
treatmentandafterresolutionoftheacutestageofthedisease
[19].However,presenceofnormalE/Aratiodoesnotexclude
presence of diastolic dysfunction as pseudonormal E/A ratio
may be the case.
The pulsed tissue Doppler also showed no signiﬁcant
changes between the controls and the patients group and
in the patient group before and after treatment except for
the prolonged IVCT and IVRT after doxorubicin treatment
which may indicate doxorubicin-induced impairment of LV
relaxation and contraction. However, our ﬁndings disagreed
with the work of Kapsuta et al. who found that the pulsed
tissue Doppler was a useful sensitive method to detect sub-
clinical myocardial damage in apparently healthy children
who received moderate doses of anthracyclines for treatment
of childhood malignancy [20]. This discrepancy could arise
due to the long duration between starting the anthracyclines
treatment and the timing of echocardiographic examination
(within 5 years) as the severity of echocardiographic LV
abnormalities increases with the duration of the followup
[21]. However, the signiﬁcant prolongation of IVCT and
IVRT observed in our study may reﬂect beginning of
impairment of the contractile and relaxation properties of
myocardium and the inception of the cardiotoxicity.
On the other hand, the 2D longitudinal strain echocar-
diography was more sensitive to detect the early cardiac
eﬀects of leukemia and that of doxorubicin treatment,
where there was signiﬁcant reduction in the peak systolic
stain in the apical long-axis view and in the global strain
both between the patients group and the controls and in
the patients group before and after doxorubicin treatment.
Our ﬁndings agreed with a number of studies concerned
with detection of cardiotoxic eﬀects of doxorubicin and
other anthracyclines. Migrino et al. studied doxorubicin-
induced cardiotoxicity in 14 male Sprague-Dawley rats.
They found that the global radial strain derived from
2-dimensional strain echocardiography was useful in the
early detection of doxorubicin cardiac injury and that the
reduction in radial strain was associated with the degree
and the onset of histologic markers of doxorubicin-induced
cardiomyopathy [17]. Tsai et al. investigated the long-term
eﬀect of anthracyclines on LV systolic function using two-
D speckle tracking echocardiography. They found that the
global longitudinal strain was reduced in patients receiving
anthracyclines (doxorubicin 309mg ±92) with mediasti-
nal radiotherapy compared to the other group receiving
mediastinal radiotherapy alone or combined radiotherapy
and regimens without anthracyclines [22] .T h es a m eﬁ n d -
ings were observed by Piegari et al., who showed in a
doxorubicin-induced cardiomyopathy model that strain and
strain rate imaging were more sensitive indices in identifying
early myocardial systolic changes induced by doxorubicin
treatment than standard echocardiographic parameters and
myocardial velocities [23]. They did the echocardiography at
2 and 4 weeks of treatment. However, the limits of studies of
Migrino et al. and Piegari et al. were that these studies were
performed on animal models and we cannot extend their
data to the human being but they can be used as a guide.8 ISRN Pediatrics
What makes 2D strain echocardiography more sensitive
than pulsed tissue Doppler is because of lack of the tethering
eﬀects from other myocardial segments which could limit
the ability of tissue Doppler imaging to quantify regional
function. The pulsed tissue Doppler directly measures the
regional function rather than tissue velocities, which are
also inﬂuenced by contractile function of other myocardial
regions due to tethering. This could limit the ability of tissue
Doppler velocities to provide quantitative data on regional
function. However, combining both techniques can give
complementary results (in our study, the prolonged IVCT
and IVRT by pulse tissue Doppler and the reduction in the
peak systolic and global strain by 2D strain echocardiog-
raphy). However, marked angle dependency is a signiﬁcant
limitation of strain rate imaging, so that correct echo beam
orientation is critical [24, 25].
5. Limitation of the Study
T h es t u d yw a sp e r f o r m e db e f o r et h ei n d u c t i o np h a s ea n d
after the end of doxorubicin treatment. So the study did not
check the late and chronic eﬀects of doxorubicin treatment
on the cardiac functions. The study also concentrated on
the left side of the heart and did not evaluate the right
side of the heart as well as for the pulmonary pressure. The
study compared the 2D longitudinal strain echocardiogram
with relatively older modalities that can assess the cardiac
function. It did not compare the 2D longitudinal strain
echocardiogram with cardiac magnetic resonance which
is considered the gold standard for assessment of LV
deformation. Also, there were many chemotherapeutic drugs
used during the study. So, the cardiotoxic eﬀects may be
caused by doxorubicin or other cytotoxic drugs. However,
due to ethical issues, we could not deprive a group of the
patients from doxorubicin treatment to be included as a
control group. The study also did not revise the eﬀect of the
cumulative doses of doxorubicin on 2D longitudinal strain
echocardiogram. Another limitation of the study is that
echocardiograms were not blindly read, so this could have
induced some bias.
6. Conclusion
The 2D longitudinal strain echocardiography was more
sensitive than conventional 2D and pulsed tissue Doppler
echocardiography in detecting the early LV doxorubicin-
induced cardiotoxicity in children with ALL. This is espe-
cially important to select the patients who need prophylactic
therapy against doxorubicin-induced cardiotoxicity.
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